Key Insights

Highlights

Success Rate

50% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

50.0%

-36.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

2Total
Early P 1 (1)
P 1 (1)

Trial Status

Completed1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (2)

Showing 2 of 2 trials
NCT03317119Phase 1Completed

Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery

NCT03272633Early Phase 1Terminated

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Showing all 2 trials

Research Network

Activity Timeline